Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension
Among patients with uncontrolled or resistant hypertension, the addition of baxdrostat to background therapy resulted in a significantly lower seated systolic blood pressure at 12 weeks than placebo. (Funded by AstraZeneca and others; BaxHTN ClinicalTrials.gov number, NCT06034743.).
Authors
- Shira Perl
- Bryan Williams (ORCID: https://orcid.org/0000-0002-8094-1841)
- Janet Wittes (ORCID: https://orcid.org/0000-0002-6625-835X)
- John M. Flack (ORCID: https://orcid.org/0000-0003-2584-5598)
- Erika Jones (ORCID: https://orcid.org/0000-0002-3569-3498)
- Jamie P. Dwyer (ORCID: https://orcid.org/0000-0002-8402-8961)
- Jakub Fronczek (ORCID: https://orcid.org/0000-0002-2110-2992)
- Jenifer M. Brown (ORCID: https://orcid.org/0000-0002-6647-639X)
- Ulrica Wilderäng (ORCID: https://orcid.org/0000-0002-0939-4128)
- Daniel S Olsson (ORCID: https://orcid.org/0000-0002-9734-0786)
- Hirotaka Shibata (ORCID: https://orcid.org/0000-0001-6506-4820)
- Michel Azizi
- Jiguang Wang
Institutions
- Brigham and Women's Hospital (US)
- Deloitte (United States) (US)
- Inserm (FR)
- Shanghai Jiao Tong University (CN)
- Oita University (JP)
- Southern Illinois University School of Medicine (US)
- Université Paris Cité (FR)
- University of Utah (US)
- Ruijin Hospital (CN)
- Groote Schuur Hospital (ZA)
- National Institute for Health and Care Research (GB)
- Sorbonne Paris Cité (FR)
- Hôpital Européen (FR)
- Shanghai Institute of Hypertension (CN)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Spain) (ES)
- University College London (GB)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1056/nejmoa2507109
- Citations
- 59
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 76.40
Funders
- AstraZeneca